STOCK TITAN
  1. Home
  2. Sec-filings
  3. RGEN
  4. [Form 4] REPLIGEN CORP Insider Trading Activity

Repligen (RGEN) CEO receives 25,890 options and 24,134 RSUs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corporation Chief Executive Officer Olivier Loeillot received new equity awards that increase his direct ownership stake. He was granted 25,890 stock options to buy Common Stock at an exercise price of $141.91 per share, expiring in 2036, vesting in three equal annual installments on March 5, 2027, 2028 and 2029. He also received 24,134 restricted stock units, each representing one share of Common Stock, vesting in equal annual installments over three years beginning on the first anniversary of the grant date. Following these awards, his direct Common Stock holdings total 58,078 shares, and the restricted stock units will be settled only in shares when they vest.

Positive

  • None.

Negative

  • None.
Insider Loeillot Olivier
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 25,890 $0.00 --
Grant/Award Common Stock 24,134 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 25,890 shares (Direct); Common Stock — 58,078 shares (Direct)
Footnotes (1)
  1. Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Loeillot Olivier
(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/05/2026A24,134(1)A$058,078D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$141.9103/05/2026A25,890 (2)03/05/2036Common Stock25,890$025,890D
Explanation of Responses:
1. Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.
/s/ Jennifer Carmichael (Attorney in Fact)03/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Repligen (RGEN) grant to its CEO Olivier Loeillot?

Repligen granted CEO Olivier Loeillot 25,890 stock options and 24,134 restricted stock units. The options carry a $141.91 exercise price, while each restricted stock unit represents one share of Common Stock delivered upon vesting.

How do Olivier Loeillot’s new Repligen (RGEN) stock options vest?

The 25,890 stock options granted to Olivier Loeillot vest in three equal annual installments. One third becomes exercisable on March 5, 2027, another third on March 5, 2028, and the final third on March 5, 2029.

What are the vesting terms of the restricted stock units granted to Repligen (RGEN) CEO?

Olivier Loeillot’s 24,134 restricted stock units vest in equal annual installments over three years. Vesting starts on the first anniversary of the grant date, and the units are settled only by delivering shares of Repligen Common Stock.

How many Repligen (RGEN) shares does CEO Olivier Loeillot hold after these awards?

After the grant of restricted stock units, Olivier Loeillot directly holds 58,078 shares of Repligen Common Stock. The 24,134 restricted stock units will add shares over time as they vest and are settled in stock.

What is the exercise price and expiration date of Repligen (RGEN) CEO’s new options?

The newly granted 25,890 stock options have an exercise price of $141.91 per share. These options expire in 2036, giving the CEO a long-dated right to purchase Repligen Common Stock if the options vest.